Pharmacokinetic data on high dose baclofen administration in unhealthy alcohol user in the ICU.

Agitation Alcohol use disorder Baclofen Intensive care unit Pharmacokinetic

Journal

Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 02 03 2019
revised: 01 07 2019
accepted: 02 07 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 24 8 2019
Statut: epublish

Résumé

In the intensive care unit, alcohol intake above the NIAAA recommendations regardless of the existence of an Alcohol Use Disorder (AUD), was associated with an increased risk of death and longer time on ventilator. This rises the hypothesis that unhealthy alcohol use may lead to specific issues when weaning the mechanical ventilation (i.e. agitation or its related complications) regardless of AUD or withdrawal syndrome. Thus, we proposed to use baclofen off-label to avoid agitation. The data presented in this article is related to the research article entitled: "Pharmacokinetics and toxicity of high-dose baclofen in ICU patients" Vourc'h et al., 2019 Data provided in this submission includes 1) the detailed methods for baclofen assay by mass spectrometric detection, 2) the supplementary population pharmacokinetic analysis presenting observed concentration vs. population or individual predicted concentration (raw data of the latter is also available), and 3) the algorithm for the adaptation of baclofen daily doses according of the renal clearance to assess the risk of toxicity in critically ill patients.

Identifiants

pubmed: 31440546
doi: 10.1016/j.dib.2019.104231
pii: S2352-3409(19)30585-2
pii: 104231
pmc: PMC6699558
doi:

Types de publication

Journal Article

Langues

eng

Pagination

104231

Références

Crit Care. 2012 Jul 26;16(4):R136
pubmed: 22835221
Trials. 2016 Aug 19;17(1):415
pubmed: 27542731
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:450-456
pubmed: 30826461

Auteurs

Mickael Vourc'h (M)

Departments of Anesthesiology and Surgical Intensive Care, Hôtel-Dieu, University Hospital of Nantes, Nantes, France.

Eric Dailly (E)

Clinical Pharmacology Department, University Hospital of Nantes, Nantes, France.

Yannick Hourmant (Y)

Departments of Anesthesiology and Surgical Intensive Care, Hôtel-Dieu, University Hospital of Nantes, Nantes, France.

Ronan Bellouard (R)

Clinical Pharmacology Department, University Hospital of Nantes, Nantes, France.

Pierre-Joachim Mahe (PJ)

Departments of Anesthesiology and Surgical Intensive Care, Hôtel-Dieu, University Hospital of Nantes, Nantes, France.

Guillaume Deslandes (G)

Clinical Pharmacology Department, University Hospital of Nantes, Nantes, France.

Matthieu Grégoire (M)

Clinical Pharmacology Department, University Hospital of Nantes, Nantes, France.

Karim Asehnoune (K)

Departments of Anesthesiology and Surgical Intensive Care, Hôtel-Dieu, University Hospital of Nantes, Nantes, France.

Classifications MeSH